ABT-925 is a selective dopamine D3 receptor (DRD3) antagonist with an in vitro affinity approximately 100 times higher for dopamine D3 receptors than for D2 receptors.
ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.
Clopidogrel HCl is the salt form of Clopidogrel (free base), an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb IIIa complex.
AZD-8055 fumarate is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
XLR11, a synthetic cannabinoid (CB) featuring a tetramethylcyclopropyl group, exhibits enhanced affinity for the CB2 receptor, common among synthetic CBs for its receptor affinity. XLR11 degradant, a frequent impurity identified in GC-MS analysis of XLR11-containing samples, originates from the thermal decomposition of XLR11, leading to an opened ring structure. This change results in a distinct fragment ion in mass spectrometry, being 15 amu heavier than XLR11's base peak. Such a signature is indicative of a McLafferty rearrangement in the degradant, a reaction not observed in the parent compound.